<strong>Carocell Bio reveals positive new preclinical data from patient biopsies</strong>

san francisco biotech

Cheadle, UK – 10 January 2022 – Today, Carocell Bio, the anti-inflammation therapeutics company, announced that its lead anti-inflammatory peptide JEL0305 shows efficacy in human inflammatory disease tissue biopsies. The candidate peptide-based treatment provides an innovative approach to treat atopic dermatitis (eczema, AD), prevent it’s recurrence and possibly delay ageing of the skin through a […]